Cytochrome P-450 CYP3A Inhibitors
"Cytochrome P-450 CYP3A Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP3A.
| Descriptor ID |
D065692
|
| MeSH Number(s) |
D27.505.389.500.503 D27.505.519.389.335.503
|
| Concept/Terms |
Cytochrome P-450 CYP3A Inhibitors- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P 450 CYP3A Inhibitors
- CYP3A Inhibitors
- Inhibitors, CYP3A
- P450 CYP3A Inhibitors
- Inhibitors, P450 CYP3A
Cytochrome P-450 CYP3A7 Inhibitors- Cytochrome P-450 CYP3A7 Inhibitors
- Cytochrome P 450 CYP3A7 Inhibitors
- P450 CYP3A7 Inhibitors
- CYP3A7 Inhibitors, P450
- Inhibitors, P450 CYP3A7
- CYP3A7 Inhibitors
- Inhibitors, CYP3A7
Cytochrome P-450 CYP3A5 Inhibitors- Cytochrome P-450 CYP3A5 Inhibitors
- Cytochrome P 450 CYP3A5 Inhibitors
- P450 CYP3A5 Inhibitors
- CYP3A5 Inhibitors, P450
- CYP3A5 Inhibitors
- Inhibitors, CYP3A5
Cytochrome P-450 CYP3A4 Inhibitors- Cytochrome P-450 CYP3A4 Inhibitors
- Cytochrome P 450 CYP3A4 Inhibitors
- P450 CYP3A4 Inhibitors
- Inhibitors, P450 CYP3A4
- CYP3A4 Inhibitors
- Inhibitors, CYP3A4
|
Below are MeSH descriptors whose meaning is more general than "Cytochrome P-450 CYP3A Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Cytochrome P-450 CYP3A Inhibitors".
This graph shows the total number of publications written about "Cytochrome P-450 CYP3A Inhibitors" by people in this website by year, and whether "Cytochrome P-450 CYP3A Inhibitors" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 2 | 0 | 2 |
| 2009 | 2 | 0 | 2 |
| 2010 | 0 | 2 | 2 |
| 2011 | 2 | 1 | 3 |
| 2012 | 1 | 1 | 2 |
| 2013 | 1 | 3 | 4 |
| 2014 | 2 | 5 | 7 |
| 2015 | 0 | 1 | 1 |
| 2017 | 0 | 2 | 2 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 1 | 2 |
| 2020 | 2 | 1 | 3 |
| 2021 | 3 | 0 | 3 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 2 | 0 | 2 |
Below are the most recent publications written about "Cytochrome P-450 CYP3A Inhibitors" by people in Profiles.
-
Development of a physiologically-based pharmacokinetic model for Ritonavir characterizing exposure and drug interaction potential at both acute and steady-state conditions. CPT Pharmacometrics Syst Pharmacol. 2025 Mar; 14(3):523-539.
-
Modeling the complexity of drug-drug interactions: A physiologically-based pharmacokinetic study of Lenvatinib with Schisantherin A/Schisandrin A. Eur J Pharm Sci. 2024 May 01; 196:106757.
-
Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087). Clin Cancer Res. 2023 12 15; 29(24):5038-5046.
-
Dietary Inhibitors of CYP3A4 Are Revealed Using Virtual Screening by Using a New Deep-Learning Classifier. J Agric Food Chem. 2022 Mar 02; 70(8):2752-2761.
-
Analyzing Potential Intestinal Transporter Drug-Drug Interactions: Reevaluating Ticagrelor Interaction Studies. Pharm Res. 2021 Oct; 38(10):1639-1644.
-
Carbon Monoxide Inhibits Cytochrome P450 Enzymes CYP3A4/2C8 in Human Breast Cancer Cells, Increasing Sensitivity to Paclitaxel. J Med Chem. 2021 06 24; 64(12):8437-8446.
-
Physiologically Based Pharmacokinetic Modeling Approach to Identify the Drug-Drug Interaction Mechanism of Nifedipine and a Proton Pump Inhibitor, Omeprazole. Eur J Drug Metab Pharmacokinet. 2021 Jan; 46(1):41-51.
-
Pharmacokinetic Enhancement of HIV Antiretroviral Therapy During Pregnancy. J Clin Pharmacol. 2020 12; 60(12):1537-1550.
-
Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Mini-Tabs Plus Ribavirin for Children Aged 3-11 Years with Hepatitis C Genotype 1a. Adv Ther. 2020 07; 37(7):3299-3310.
-
A Simple Methodology to Differentiate Changes in Bioavailability From Changes in Clearance Following Oral Dosing of Metabolized Drugs. Clin Pharmacol Ther. 2020 08; 108(2):306-315.